Modeling Between-Subject Variability in Subcutaneous Absorption of a Long-Acting Insulin Glargine 100 U/mL by a Nonlinear Mixed Effects Approach

Author(s):  
Edoardo Faggionato ◽  
Michele Schiavon ◽  
Chiara Dalla Man
Metabolites ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 235
Author(s):  
Edoardo Faggionato ◽  
Michele Schiavon ◽  
Chiara Dalla Man

Despite the great progress made in insulin preparation and titration, many patients with diabetes are still experiencing dangerous fluctuations in their blood glucose levels. This is mainly due to the large between- and within-subject variability, which considerably hampers insulin therapy, leading to defective dosing and timing of the administration process. In this work, we present a nonlinear mixed effects model describing the between-subject variability observed in the subcutaneous absorption of fast-acting insulin. A set of 14 different models was identified on a large and frequently-sampled database of lispro pharmacokinetic data, collected from 116 subjects with type 1 diabetes. The tested models were compared, and the best one was selected on the basis of the ability to fit the data, the precision of the estimated parameters, and parsimony criteria. The selected model was able to accurately describe the typical trend of plasma insulin kinetics, as well as the between-subject variability present in the absorption process, which was found to be related to the subject’s body mass index. The model provided a deeper understanding of the insulin absorption process and can be incorporated into simulation platforms to test and develop new open- and closed-loop treatment strategies, allowing a step forward toward personalized insulin therapy.


2020 ◽  
Vol 67 (2) ◽  
pp. 624-631 ◽  
Author(s):  
Michele Schiavon ◽  
Roberto Visentin ◽  
Clemens Giegerich ◽  
Thomas Klabunde ◽  
Claudio Cobelli ◽  
...  

Diabetes Care ◽  
2000 ◽  
Vol 23 (5) ◽  
pp. 644-649 ◽  
Author(s):  
L. Heinemann ◽  
R. Linkeschova ◽  
K. Rave ◽  
B. Hompesch ◽  
M. Sedlak ◽  
...  

Diabetes Care ◽  
2013 ◽  
Vol 37 (3) ◽  
pp. 659-665 ◽  
Author(s):  
Richard M. Bergenstal ◽  
Julio Rosenstock ◽  
Edward J. Bastyr ◽  
Melvin J. Prince ◽  
Yongming Qu ◽  
...  

Diabetes Care ◽  
2005 ◽  
Vol 28 (12) ◽  
pp. 2983-2983 ◽  
Author(s):  
F. J. Ampudia-Blasco ◽  
J. Girbes ◽  
R. Carmena

2021 ◽  
Vol 8 (1) ◽  
pp. 31-36
Author(s):  
Mark R Burge ◽  
Imaneh Fallahi ◽  
Madhavi Garimella ◽  
Steve Mitchell

Background: Insulin detemir is long-acting insulin analog that is weight-neutral compared with other long-acting insulins in patients with type 1 diabetes. One mechanism for this may be an effect of insulin detemir to enhance satiety. We hypothesized that type 1 diabetes patients on insulin detemir will eat fewer calories when presented with a standardized buffet meal following a 24-hour fast as compared to those on insulin glargine. Methods: Ten subjects with C-peptide negative type 1 diabetes participated in a randomized, double-blind crossover study in which they received equivalent doses of either insulin detemir or insulin glargine twice daily for at least 3 weeks. They were subsequently admitted to the UNM Clinical Research Unit for a 24-hour fast, after which they were allowed to eat to satiety from a standardized buffet. Caloric consumption, hunger score and body compositions were measured. Leptin, Ghrelin and Peptide YY were assessed at baseline, after 24-hour fast, and after ingestion of the meal. Results: Subjects were aged 35±11 years, had diabetes for 18±11 years, had A1c levels of 8±1% and BMI of 30±8 kg/m2. Short acting insulin doses were higher for subjects receiving insulin detemir versus insulin glargine (p<0.001). Hunger scores, total energy ingested following the 24-hour fast, and Resting Energy Expenditure did not significant differ between the two study conditions. Conclusion: The weight-neutrality of insulin detemir in type 1 diabetes is not attributable to reduced caloric intake following a fast, or to serum satiety factors.  


Sign in / Sign up

Export Citation Format

Share Document